Skip to content
10-Q

Quarterly Report

AUTOLUS THERAPEUTICS PLC AUTL

0001730463-26-000065

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 266.16M sh
Shares Diluted Q1 2026 · Mar 31, 2026 266.14M sh
Shares Diluted Q1 2026 · Mar 31, 2025 266.13M sh
Capex Q1 2026 · Mar 31, 2026 $2.69M
Capex Q1 2026 · Mar 31, 2025 $8.24M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$65.32M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$75.57M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $130.93M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $104.13M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $95.8M
Stockholders Equity Q1 2026 · Mar 31, 2026 $108.83M
Stockholders Equity Q1 2026 · Dec 31, 2025 $178.13M
Stockholders Equity Q1 2026 · Mar 31, 2025 $371.11M
Stockholders Equity Q1 2026 · Dec 31, 2024 $427.33M
Current Liabilities Q1 2026 · Mar 31, 2026 $63.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $73.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $418.24M
Total Liabilities Q1 2026 · Dec 31, 2025 $410.94M
Current Assets Q1 2026 · Mar 31, 2026 $368.84M
Current Assets Q1 2026 · Dec 31, 2025 $435.92M
Total Assets Q1 2026 · Mar 31, 2026 $527.07M
Total Assets Q1 2026 · Dec 31, 2025 $589.07M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.27
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.26
Eps Basic Q1 2026 · Mar 31, 2026 −$0.27
Eps Basic Q1 2026 · Mar 31, 2025 −$0.26
Sga Expense Q1 2026 · Mar 31, 2026 $39.95M
Sga Expense restated Q1 2026 · Mar 31, 2025 $29.54M
Rd Expense Q1 2026 · Mar 31, 2026 $21.21M
Rd Expense Q1 2026 · Mar 31, 2025 $26.73M
Net Income Q1 2026 · Mar 31, 2026 −$71.6M
Net Income Q1 2026 · Mar 31, 2025 −$70.16M
Operating Income Q1 2026 · Mar 31, 2026 −$59.51M
Operating Income Q1 2026 · Mar 31, 2025 −$65.24M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $24.57M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $17.95M
Revenue Q1 2026 · Mar 31, 2026 $26.22M
Revenue Q1 2026 · Mar 31, 2025 $8.98M